16364413

Source:http://linkedlifedata.com/resource/pubmed/id/16364413

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0002403, umls-concept:C0008838, umls-concept:C0032207, umls-concept:C0205102, umls-concept:C0334227, umls-concept:C0439855, umls-concept:C0683598, umls-concept:C1140680
pubmed:issue	1
pubmed:dateCreated	2006-6-16
pubmed:abstractText	The resistance of tumor cells to cisplatin remains a major cause of treatment failure in cancer patients. In this study, the ability of Pt(IV) complex with adamantylamine-LA-12 and its reduced counterpart with lower oxidation state Pt(II)-LA-9 to overcome intrinsic cisplatin resistance was investigated.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0365304
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Amantadine, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Poly(ADP-ribose) Polymerases, http://linkedlifedata.com/resource/pubmed/chemical/Vault Ribonucleoprotein Particles, http://linkedlifedata.com/resource/pubmed/chemical/bis(acetato)(1-adamantylamine)ammine..., http://linkedlifedata.com/resource/pubmed/chemical/major vault protein
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0090-8258
pubmed:author	pubmed-author:BlanárováOlgaO, pubmed-author:FedorockoPeterP, pubmed-author:HofmanováJirinaJ, pubmed-author:HorváthViktorV, pubmed-author:KozubíkAloisA, pubmed-author:KroutilAlesA, pubmed-author:SoucekKarelK, pubmed-author:SovaPetrP, pubmed-author:Svihálková-SindlerováLenkaL
pubmed:issnType	Print
pubmed:volume	102
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	32-40
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:16364413-Adenocarcinoma, pubmed-meshheading:16364413-Amantadine, pubmed-meshheading:16364413-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16364413-Blotting, Western, pubmed-meshheading:16364413-Cell Cycle, pubmed-meshheading:16364413-Cell Growth Processes, pubmed-meshheading:16364413-Cell Line, Tumor, pubmed-meshheading:16364413-Cisplatin, pubmed-meshheading:16364413-DNA, Neoplasm, pubmed-meshheading:16364413-Drug Resistance, Neoplasm, pubmed-meshheading:16364413-Female, pubmed-meshheading:16364413-Humans, pubmed-meshheading:16364413-Neoplasm Proteins, pubmed-meshheading:16364413-Organoplatinum Compounds, pubmed-meshheading:16364413-Ovarian Neoplasms, pubmed-meshheading:16364413-Poly(ADP-ribose) Polymerases, pubmed-meshheading:16364413-Vault Ribonucleoprotein Particles
pubmed:year	2006
pubmed:articleTitle	Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
pubmed:affiliation	Laboratory of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, 61265 Brno, Czech Republic.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't